Global distribution and prevalence of hepatitis C virus genotypes.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. · 2015
Read Global distribution and prevalence of hepatitis C virus genotypes. by Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4303918.txt.
Introduction
Jane P Messina and six co-authors produced the first full world survey of hepatitis C virus genotypes. Their study appeared in Hepatology in 2015. The virus comes in several genotypes whose spread differs by region, and that patchwork complicates work on vaccines and on treatments meant to work against every type.
The team reviewed genotype studies published from 1989 to 2013 and combined them with overall infection estimates from the Global Burden of Disease project. For countries with no genotype data, values were inferred from neighbors and patterns. The resulting maps show which genotypes dominate each region and where data are missing, a base for planning treatment programs.
Catalog record
| CREATOR | Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Global Distribution and Prevalence of Hepatitis C Virus Genotypes By Jane P Messina, Isla Humphreys, Abraham Flaxman, Anthony Brown, Graham S Cooke, Oliver G Pybus, Eleanor Barnes Published in: Hepatology (Baltimore, Md.) DOI: 10.1002/hep.27259 ABSTRACT Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations in genotype prevalence. This poses a challenge to the improved development of vaccines and pan-genotypic treatments, which require the consideration of global trends in HCV genotype prevalence. Here we provide the first comprehensive survey of these trends. To approximate national HCV genotype prevalence, studies published between 1989 and 2013 reporting HCV genotypes are reviewed and combined with overall HCV prevalence estimates from the Global Burden of Disease (GBD) project. We also generate regional and global genotype prevalence estimates, inferring data for countries lacking genotype information. We include 1,217 studies in our analysis, representing 117 countries and 90% of the global population. We calculate that HCV genotype 1 is the most prevalent worldwide, comprising 83.4 million cases (46.2% of all HCV cases), approximately one-third of which are in East Asia. Genotype 3 is the next most prevalent globally (54.3 million, 30.1%); genotypes 2, 4, and 6 are responsible for a total 22.8% of all cases; genotype 5 comprises the remaining <1%. While genotypes 1 and 3 dominate in most countries irrespective of economic status, the largest proportions of genotypes 4 and 5 are in lower-income countries. Conclusion: Although genotype 1 is most common worldwide, nongenotype 1 HCV cases—which are less well served by advances in vaccine and drug development—still comprise over half of all HCV cases. Relative genotype proportions are needed to inform healthcare models, which must be geographically tailored to specific countries or regions in order to improve access to new treatments. Genotype surveillance data are needed from many countries to improve estimates of unmet need. (Hepatology 2015;61:77–87) Hepatitis C virus (HCV) is a globally prevalent pathogen and a leading cause of death and morbidity.1 The most recent estimates of disease burden show an increase in seroprevalence over the last 15 years to 2.8%, equating to >185 million infections worldwide.2 Persistent HCV infection is associated with the development of liver cirrhosis, hepatocellular cancer, liver failure, and death,3 and HCV is now the most common cause of death in HIV-positive patients on highly active antiretroviral therapy.4 While the incidence rate of HCV infection is apparently decreasing in the developed world, deaths from liver disease secondary to HCV infection will continue to increase over the next 20 years.5 Historically, HCV drug therapy has depended on interferon-α (administered by injection) and ribavirin over many months and is associated with severe side effects. The resources required for treating HCV patients with such drugs have been a considerable barrier for healthcare systems in many low and/or lower-middle income countries, despite treatment outcomes that are comparable to those in well-resourced settings.6–8 That said, the coming decade should witness a remarkable transformation in the treatment of HCV infection. While the first generation of new direct-acting antivirals (DAAs) were given in combination with interferon and ribavirin, and thus added to the burden of side effects,9,10 second-generation DAA therapies with minimal side effects and shortened courses of therapy are associated with cure rates of more than 90% in Phase II or III studies.11 Moreover, multiple DAA therapies targeting distinct HCV proteins have been developed and, when given in combination, will obviate the need for interferon treatment.12–14 Thus, if DAAs are made affordable, the treatment of HCV across the globe will become a realistic option for the first time. HCV exhibits an extraordinarily high degree of genetic diversity—substantially greater than that of the HIV-1 pandemic—creating a major challenge for the development of both HCV vaccines and pan-genotypic drug therapies.15 At present, the duration of treatment, cure rates, and the need for adjuvant interferon and ribavirin with the new DAA therapies remain dependent in part on HCV genotype and subtype. Therefore, the development of national treatment strategies using DAA therapies requires a detailed understanding of relative HCV genotype prevalence and subtypes. Furthermore, the first prophylactive T-cell vaccines that aim to prevent persistent HCV infection are currently in Phase II efficacy testing, with further candidates moving into human studies.16 The first generation of vaccines in development contain a subtype-1b immunogen in viral vectors that are deployed in a heterologous prime-boost regimen.17 In countries with mixed genotype infection, crossreactive immunity will depend on the generation of an immune response that targets HCV antigens that are conserved between genotypes. An alternative strategy, however, would be to develop geographically tailored vaccine immunogens for deployment at a country or regional level where detailed information on viral subtypes is available. Overall, the rational testing of HCV vaccine candidates will require a comprehensive country-level understanding of relative subtype prevalence. HCV strains are classified into seven recognized genotypes (1-7) on the basis of phylogenetic and sequence analyses of whole viral genomes.18 HCV strains belonging to different genotypes differ at 30-35% of nucleotide sites. Within each genotype, HCV is further classified into 67 confirmed and 20 provisional subtypes. Strains that belong to the same subtype differ at <15% of nucleotide sites.19 The contemporary global geographic distribution of HCV genotypes is complex. It has already been established that a few subtypes—specifically 1a, 1b, 2a, and 3a—are widely distributed across the globe and account for a large proportion of HCV infections in high-income countries. These so-called “epidemic subtypes” are thought to have spread rapidly in the decades prior to the discovery of HCV by way of infected blood, blood products, injecting drug use, and other routes.20–22 Many other HCV subtypes are considered “endemic” strains; these are comparatively rare and have circulated for long periods of time in more restricted regions: endemic strains from genotypes 1 and 2 are primarily in West Africa, 3 in south Asia, 4 in Central Africa and the Middle East, 5 in Southern Africa, and 6 in South East Asia.20,23,24 To date, only one genotype 7 infection has been reported; it was isolated in Canada from a Central African immigrant.25 The global distribution of HCV genetic variation has likely been influenced by historical and contemporary trends in human migration. For example, strains from West Africa appear to have been transferred to the Americas by way of the trans-Atlantic slave trade.26 Here we are the first to estimate the relative prevalence of HCV genotypes globally by region and by country where data permitted. The data described provide a platform for the rational deployment and efficacy testing of new DAA therapies and vaccines for HCV. MATERIALS AND METHODS We searched PubMed (http://www.pubmed.gov) for all articles containing the terms “HCV” or “hepatitis c virus” and “genotype” or “subtype” published between 1989 (the year that HCV was discovered) and 2013. As a standardized genotype classification system was not present before 1994, we converted HCV genotypes or serotypes in articles published between 1989 and 1994 to the consensus nomenclature proposed by Simmonds et al.18 In many studies HCV cases were classified at the genotype level but not at the subtype level. If articles contained the same patient cohort then this cohort was only counted once. We recorded the number of cases of each HCV genotype identified along with the size of the study population. Some individuals